Pacific Northwest addiction treatment network
Clinical Trials Network: Pacific Northwest Node
This program runs studies of new medicines, behavioral therapies, overdose-prevention, and harm-reduction approaches for people affected by opioid, methamphetamine, and cannabis use in the Pacific Northwest.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11261217 on NIH RePORTER |
What this research studies
If I join, the Pacific Northwest Node will run and support clinical studies that try new medicines, behavioral therapies, harm-reduction tools, and technologies for opioid, methamphetamine, and cannabis problems. They plan to work with more clinics and primary care offices, partner with community groups and policy organizations, and include youth, families, and diverse treatment settings so more people can join. Studies include real-world, pragmatic trials, comparative effectiveness, implementation work, and data-science projects that use patient data and samples to learn what works best in everyday care. Participating sites may offer medications for opioid use disorder (MOUD), overdose-prevention services, neuromodulation approaches, and other behavioral or pharmacologic treatments depending on the specific study.
Who could benefit from this research
Good fit: Ideal candidates include people with opioid, methamphetamine, or cannabis use concerns (including youth and family-impacted individuals) receiving care at participating clinics or primary care settings in the Pacific Northwest.
Not a fit: People without substance-use concerns, those outside the Pacific Northwest, or individuals who do not meet specific study eligibility rules may not benefit from these projects.
Why it matters
Potential benefit: If successful, this work could expand access to effective treatments and reduce overdoses and harms for people with substance use disorders in the region.
How similar studies have performed: The NIDA CTN has a long track record of producing practice-changing findings for MOUD and behavioral treatments, though work on methamphetamine, novel neuromodulation, and some technology-based approaches remains newer and less proven.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Hatch, Mary Akiko — University of Washington
- Study coordinator: Hatch, Mary Akiko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.